Coronavirus Update: Synairgen Tests First Inhaled Candidate, No New China Cases
While Survey Shows Looming Crisis In Trial Recruitment
Executive Summary
More studies are being launched into possible treatments for patients hospitalised with COVID-19, with Roche launching a Phase III, placebo-controlled trial of Actemra.
You may also be interested in...
Synairgen Stock Soars 420% On Promise Of Inhaled COVID-19 Drug
Preliminary results show that hospitalized coronavirus patients who received Synairgen's inhaled interferon beta product had a 79% lower risk of developing severe disease compared with placebo.
Coronavirus Update: Drug Shortages On Horizon, Firms Offer Medical Staff For The Fight, More Studies Start
Fears over shortages of drugs needed for ventilated patients rise, while Merck & Co, Pfizer and Lilly allow their medics to volunteer, and attention turns to beta-interferon products and NK cell therapies to fight the virus.
Provention Announces First Clinical Trial Delay, Others Follow As COVID-19 Concerns Persist
Rather than expose patients and others to SARS-CoV-2, Provention opted to pause a Phase III type 1 diabetes trial. Addex and Iveric have since delayed trial initiations and more studies are likely to be impacted as coronavirus concerns mount.